Due to the paucity of scientific evidence supporting the use of PD-1/PD-L1 inhibitors in combination with other drugs in the second or later-line treatment of patients with advanced non-small cell lung cancer, a number of clinical studies are being conducted worldwide to further examine the viability of combination regimens. The gene discussed is CD274; the disease is non-small cell lung carcinoma.